Ownership history in MACQUARIE GROUP LTD Β· 35 quarters on record
This page tracks every 13F SEC filing in which MACQUARIE GROUP LTD reported a position in PUMA BIOTECHNOLOGY INC (PBYI). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π MACQUARIE GROUP LTD underperformed the S&P 500 by β30.4% annually on this PBYI position. Timing score: 47% (8/17 decisions correct). Average cost basis: $43.34. Maximum drawdown during holding period: β99.0%.
β Significantly underperformed the S&P 500 by 30.4% ann.
34 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
8 of 17 add/trim decisions correct
Best entry: $5.30 (2024 Q1) Β· Worst: $236.11 (2015 Q1)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
11 adds Β· 6 trims. Bought during 6 of 22 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size